⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794096 | 1.00 | — | — | |
| SCHEMBL8238 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL25253821 | 0.98 | GNAI3 (0.41) | — | |
| Hydrochloric Acid SCHEMBL16445991 | 0.98 | GNAI3 (0.41) | — | |
| SCHEMBL1248249 | 0.86 | HPGD (0.35) | — | |
| SCHEMBL1421166 | 0.86 | HPGD (0.35) | — | |
| SCHEMBL477321 | 0.86 | HPGD (0.35) | — | |
| SCHEMBL112479 | 0.85 | GNAI3 (0.44) | — | |
| SCHEMBL18226165 | 0.85 | HPGD (0.39) | — | |
| SCHEMBL2145106 | 0.85 | HPGD (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 753 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | claimed |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | claimed |
| EP-3661941-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-06-10 | — | — | EP | claimed |
| US-10239879-B2 | Process for producing purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-26 | — | — | US | claimed |
| WO-2019025099-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | claimed |
| CN-102656179-A | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA CO LTD | 2012-09-05 | — | — | CN | claimed |
| EP-2476667-A2 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. (US) | 2012-07-18 | — | — | EP | claimed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | claimed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | claimed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | claimed |
| JP-2006519232-A | — | — | 2006-08-24 | — | — | JP | claimed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | claimed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1503980-A2 | SUBSTITUTED HYDROXYETHYLAMINES | Elan Pharmaceuticals, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| WO-2003072535-A2 | SUBSTITUTED HYDROXYETHYLAMINES | ELAN PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-5530121-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | claimed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| CN-119998264-A | Novel bicyclic heterocyclyl compounds and uses thereof | 第一药品株式会社 | 2025-05-13 | — | — | CN | disclosed |
| US-20240279338-A1 | Combination Treatment of Cancer | ARES TRADING SA (CH) | 2024-08-22 | — | — | US | disclosed |
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| WO-2024148210-A1 | CYCLIN-DEPENDENT KINASE 12 MODULATORS AND THERAPEUTIC USES THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | WO | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-20 | — | — | US | disclosed |
| WO-2024114658-A1 | SUBSTITUTED 1-PHENYL-3, 4-DIHYDROPYRIDO [3, 4-D] PYRIMIDIN-2-ONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-118076593-A | 3CLpro protease inhibitors | 上海齐鲁制药研究中心有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024105007-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| CN-117940427-A | Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof | 卡里克治疗有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024084390-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240132505-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240124468-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2024-04-18 | — | — | US | disclosed |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | AXIAL THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240109866-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20240101563-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2024-03-28 | — | — | US | disclosed |
| WO-2024062250-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2024-03-28 | — | — | WO | disclosed |
| EP-3914586-B1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | AVEDRO INC (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024056077-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-21 | — | — | WO | disclosed |
| US-20240083886-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-03-14 | — | — | US | disclosed |
| US-20240083899-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-14 | — | — | US | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| WO-2024044744-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| US-20240059673-A1 | SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
| WO-2024039860-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024032561-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-02-15 | — | — | WO | disclosed |
| US-11897885-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-02-13 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-116478145-B | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024023266-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| CN-117447449-A | PARP1 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023250157-A9 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4299575-A1 | BTK AND/OR BTK C481S SMALL MOLECULE INHIBITOR AND USE THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023250157-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-3724194-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| US-20230405157-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023219952-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116997548-A | HTT modulators for the treatment of huntington's disease | CHDI基金会股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-4267559-A1 | SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4267142-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969920-A | Fused pyridazine derivative, preparation method and medical application thereof | 上海辉启生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4262802-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4255420-A1 | COMPOUNDS FOR INHIBITING INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | Lieber Institute, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4255904-A2 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2023-10-11 | — | — | EP | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-4229049-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023143482-A1 | 2-AMINOPYRIMIDINE COMPOUND OR SALT, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-3794002-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| CN-116478145-A | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4211118-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | Cerevance, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023133225-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-116406272-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| WO-2023125737-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-3281943-B1 | PROCESS FOR PRODUCING PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2023-06-28 | — | — | EP | disclosed |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023107705-A1 | BICYCLIC AMINES AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183251-A1 | BICYCLIC AMINES AS CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-15 | — | — | US | disclosed |
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |
| EP-3590938-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2023-05-24 | — | — | EP | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| EP-4171547-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Axial Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| WO-2023066363-A1 | PARP-1 DEGRADATION AGENT AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| CN-113354635-B | Pyrrolidine integrin regulator and application thereof | 清药同创(北京)药物研发中心有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| EP-4157263-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | The Regents Of The University Of Michigan (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230092890-A1 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
| EP-4149937-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI Foundation, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230083495-A1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2023-03-16 | — | — | US | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| EP-3592741-B1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4126839-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126849-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115666553-A | TLR2 modulator compounds, and pharmaceutical compositions and uses thereof | 轴向治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230027088-A1 | EP300/CBP INHIBITOR | HINOVA PHARMACEUTICALS INC. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230015914-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| CN-115583946-A | Heterocyclic compounds and their use as CDK inhibitors | 赛诺哈勃药业（成都）有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| CN-115304606-A | Degradation agent for simultaneously targeting BTK and GSPT1 proteins | 清华大学 | 2022-11-08 | — | — | CN | disclosed |
| EP-4065107-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2022-10-05 | — | — | EP | disclosed |
| CN-115151256-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-113105475-B | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-111217816-B | FLT3 kinase inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2022-08-16 | — | — | CN | disclosed |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-07-19 | — | — | US | disclosed |
| WO-2022147302-A1 | 4-PHENYL-INDOLE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2022-07-07 | — | — | WO | disclosed |
| CN-110511209-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2022-07-05 | — | — | CN | disclosed |
| WO-2022140647-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140326-A1 | SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11370778-B2 | Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases | Enterprise Therapeutics Limited (GB) | 2022-06-28 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022132936-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022125524-A1 | COMPOUNDS FOR INHIBITING INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-114605414-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20220177474-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| WO-2022117882-A2 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2022-06-09 | — | — | WO | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| CN-110214141-B | Benzodiazolium compounds as ENaC inhibitors | 企业治疗学有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-114502540-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
| EP-3433246-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022078380-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3976604-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976192-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11292795-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-04-05 | — | — | US | disclosed |
| CN-114258392-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114222739-A | Sulfonylurea derivatives and use thereof | 诺瑟拉有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2022053823-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | Cerevance, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| CN-114133394-A | Compound selectively aiming at activity of cell cycle dependent kinase 12, preparation method and medical application | 赛诺哈勃药业（成都）有限公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3956031-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | Pfizer Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11242337-B2 | Compounds useful for treating gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| WO-2022003557-A1 | NOVEL INHIBITORS OF AUTOTAXIN | CADILA HEALTHCARE LIMITED (IN) | 2022-01-06 | — | — | WO | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| CN-113811527-A | Bis (bisaziridine) derivatives as photocrosslinkers for treating corneal ectasia disorders | 艾弗德罗股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| WO-2021249896-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| EP-3697788-B1 | BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-3917936-A1 | ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS | Guangdong Newopp Biopharmaceuticals Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021242753-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021242923-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| EP-3914586-A1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | Avedro Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | disclosed |
| US-20210355117-A1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-11-18 | — | — | US | disclosed |
| WO-2021231571-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210346382-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2021-11-11 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| CN-113614095-A | Alkylboronic acids as arginase inhibitors | 广东新契生物医药科技有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-11154554-B2 | Therapeutic combinations of a MEK inhibitor and a BTK inhibitor | Acera Pharma B.V. (NL) | 2021-10-26 | — | — | US | disclosed |
| US-20210322408-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | ACERTA PHARMA BV (NL) | 2021-10-21 | — | — | US | disclosed |
| EP-3893879-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3894396-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2021202775-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| CN-109641906-B | Heteroaryl substituted aminopyridine compounds | 百时美施贵宝公司 | 2021-10-01 | — | — | CN | disclosed |
| EP-3883925-A1 | CYCLIC UREAS | Sironax Ltd (KY) | 2021-09-29 | — | — | EP | disclosed |
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCE, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3877390-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | Prelude Therapeutics, Incorporated (US) | 2021-09-15 | — | — | EP | disclosed |
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| CN-113181362-A | Agent for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2021-07-30 | — | — | CN | disclosed |
| CN-113166173-A | Spiro-sulfonamide derivatives as inhibitors of myeloid leukemia 1(MCL-1) protein | 普莱鲁德疗法有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113164477-A | Pyrazolopyridine inhibitors of C-JUN-N-terminal kinase and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| CN-113105475-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2021-07-13 | — | — | CN | disclosed |
| US-20210206765-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-07-08 | — | — | US | disclosed |
| EP-3845530-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2021-07-07 | — | — | EP | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| CN-108368094-B | Non-steroidal glucocorticoid receptor modulators for topical drug delivery | 利奥制药有限公司 | 2021-07-02 | — | — | CN | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| US-11046716-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210188855-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-06-24 | — | — | US | disclosed |
| WO-2021126693-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3544981-B1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| CN-112574200-B | Small molecule inhibitors of BTK and/or mutant C481S of BTK | 安润医药科技（苏州）有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| US-11021482-B2 | Pyrrolopyrimidine ITK inhibitors | Adaris Therapeutics, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| CN-108290861-B | 1-cyano-pyrrolidine derivatives as USP30 inhibitors | 特殊治疗有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112707893-A | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2021-04-27 | — | — | CN | disclosed |
| EP-3808747-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| CN-112638373-A | Cyclin-dependent kinase inhibitors | 金耐特生物制药公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112574200-A | Small molecule inhibitors of BTK and/or mutant C481S of BTK | 安润医药科技（苏州）有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-109526219-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| EP-3789027-A1 | BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2021-03-09 | — | — | US | disclosed |
| CN-108884068-B | 1-cyano-pyrrolidine derivatives as DUB inhibitors | 特殊治疗有限公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3277677-B1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-02-24 | — | — | EP | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| CN-112236431-A | Purinone compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20210009593-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| CN-108239069-B | Inhibitor for fibroblast growth factor receptor and application thereof | 南京药捷安康生物科技有限公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-3508482-B1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) | 2020-12-16 | — | — | EP | disclosed |
| US-20200385370-A1 | APPARATUS FOR REMOVING BAD ODOR FROM TOILET | SYNBLIA THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3747472-A1 | THERAPEUTIC COMBINATIONS OF A CD19 INHIBITOR AND A BTK INHIBITOR | Acerta Pharma B.V. (NL) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020240492-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-12-03 | — | — | WO | disclosed |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| CN-108349951-B | Bispyridazine compound | 阿斯利康(瑞典)有限公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-107108583-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | disclosed |
| WO-2020212865-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3724194-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| US-10807981-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| EP-3715346-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | Dana-Farber Cancer Institute (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3704104-A1 | IRAK4 INHIBITORS AND USES THEREOF | Synblia Therapeutics, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200262838-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-10744139-B2 | Inhibitors of fibroblast growth factor receptor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-08-18 | — | — | US | disclosed |
| CN-111542516-A | IRAK4 inhibitors and uses thereof | 新标立亚医疗有限公司 | 2020-08-14 | — | — | CN | disclosed |
| WO-2020160707-A1 | ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-08-13 | — | — | WO | disclosed |
| EP-3190116-B1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-10730912-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD. (CH) | 2020-08-04 | — | — | US | disclosed |
| US-20200239442-A1 | BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES | Enterprise Therapeutics Limited (GB) | 2020-07-30 | — | — | US | disclosed |
| WO-2020154673-A1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | AVEDRO, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| CN-109970741-B | Aminopyridazinone compounds as protein kinase inhibitors | 江苏恒瑞医药股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-23 | — | — | US | disclosed |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| WO-2020123925-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | US | disclosed |
| EP-3661941-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-06-10 | — | — | EP | disclosed |
| CN-111217816-A | FLT3 kinase inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2020-06-02 | — | — | CN | disclosed |
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
| CN-107434803-B | Inhibitors of histone demethylases | 吉利德科学公司 | 2020-05-05 | — | — | CN | disclosed |
| EP-3383859-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-04-29 | — | — | EP | disclosed |
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| US-20200108070-A2 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-04-09 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | disclosed |
| WO-2020045941-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 대웅제약 | 2020-03-05 | — | — | WO | disclosed |
| US-20200069796-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| US-20200069668-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20200055877-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-20 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20200048256-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3112368-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2020-02-12 | — | — | EP | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
| CN-110540538-A | Inhibitors of influenza virus replication | VERTEX PHARMA | 2019-12-06 | — | — | CN | disclosed |
| EP-3565808-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3350175-B1 | NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS FOR LOCAL DRUG DELIVERY | LEO PHARMA AS (DK) | 2019-11-06 | — | — | EP | disclosed |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2019-10-17 | — | — | US | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| US-20190314369-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | ACERTA PHARMA BV (NL) | 2019-10-17 | — | — | US | disclosed |
| US-20190315748-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284204-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| CN-110214141-A | Benzodiazole compound as ENaC inhibitor | 企业治疗学有限公司 | 2019-09-06 | — | — | CN | disclosed |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10399996-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | disclosed |
| US-10370377-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-06 | — | — | US | disclosed |
| US-20190231775-A1 | Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase | ACERTA PHARMA BV (NL) | 2019-08-01 | — | — | US | disclosed |
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-20190209591-A1 | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2019-07-11 | — | — | US | disclosed |
| US-20190209564-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO LTD (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-3508482-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Missions Therapeutics Limited (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2019-06-27 | — | — | US | disclosed |
| WO-2019115774-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| US-10314844-B2 | Inhibitors of Bruton's tyrosine kinase | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190169192-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20190169172-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2019-06-06 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3212647-B1 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG A ST CO LTD (KR) | 2019-04-03 | — | — | EP | disclosed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-10239879-B2 | Process for producing purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| CN-109526219-A | Benzsulfamide and its purposes as therapeutic agent | 泽农医药公司 | 2019-03-26 | — | — | CN | disclosed |
| US-10233185-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| WO-2019025099-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | disclosed |
| US-10196382-B2 | bis-Pyridazine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-02-05 | — | — | US | disclosed |
| EP-3433246-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| US-10189787-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20190022092-A1 | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist | ACERTA PHARMA BV (NL) | 2019-01-24 | — | — | US | disclosed |
| US-20190008869-A1 | Therapeutic Combinations of an Antifolate and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2019-01-10 | — | — | US | disclosed |
| US-20190008859-A1 | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2019-01-10 | — | — | US | disclosed |
| US-20180369244-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2018-12-27 | — | — | US | disclosed |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| CN-109071563-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2018-12-21 | — | — | CN | disclosed |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-12-04 | — | — | US | disclosed |
| EP-3402503-A1 | THERAPEUTIC COMBINATIONS OF AN ANTIFOLATE AND A BTK INHIBITOR | Acerta Pharma B.V. (NL) | 2018-11-21 | — | — | EP | disclosed |
| CN-106083887-B | Inhibit the compound of BTK and/or JAK3 kinase activity | 北京韩美药品有限公司 | 2018-11-20 | — | — | CN | disclosed |
| US-20180318304-A1 | Methods of Using BTK Inhibitors to Treat Dermatoses | ACERTA PHARMA BV (NL) | 2018-11-08 | — | — | US | disclosed |
| US-10112957-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3389664-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | Raze Therapeutics Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3386992-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | Janssen Pharmaceutica, N.V. (BE) | 2018-10-17 | — | — | EP | disclosed |
| US-10100084-B2 | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity | POLYPHOR LTD. (CH) | 2018-10-16 | — | — | US | disclosed |
| EP-3383859-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. | Mission Therapeutics Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| EP-3380468-A1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-03 | — | — | EP | disclosed |
| US-20180258080-A1 | NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS FOR LOCAL DRUG DELIVERY | LEO PHARMA A/S (DK) | 2018-09-13 | — | — | US | disclosed |
| WO-2018163066-A1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2018-09-13 | — | — | WO | disclosed |
| US-20180250400-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180244675-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-08-30 | — | — | US | disclosed |
| US-20180243311-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | GILEAD SCIENCES, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20180207154-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-07-26 | — | — | US | disclosed |
| EP-3350175-A1 | NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS FOR LOCAL DRUG DELIVERY | Leo Pharma A/S (DK) | 2018-07-25 | — | — | EP | disclosed |
| EP-3347008-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| CN-108290861-A | 1- cyano-pyrolidin derivatives as USP30 inhibitor | 特殊治疗有限公司 | 2018-07-17 | — | — | CN | disclosed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
| WO-2018129552-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180193337-A1 | Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase | ACERTA PHARMA BV (NL) | 2018-07-12 | — | — | US | disclosed |
| EP-2935244-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | SELVITA S A (PL) | 2018-06-27 | — | — | EP | disclosed |
| US-20180170933-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-10000535-B2 | Template-fixed peptidomimetics | POLYPHOR LTD. (CH) | 2018-06-19 | — | — | US | disclosed |
| US-9999622-B2 | Pyrazolothiazole compound and medicine comprising same | NIPPON SHINYAKU CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| CN-106065017-B | Inhibit the compound of BTK and/or JAK3 kinase activities | 北京韩美药品有限公司 | 2018-06-01 | — | — | CN | disclosed |
| US-9981966-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| EP-3313832-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9949971-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2018-04-24 | — | — | US | disclosed |
| WO-2018071343-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-04-19 | — | — | WO | disclosed |
| US-9937171-B2 | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase | ACERTA PHARMA B.V. (NL) | 2018-04-10 | — | — | US | disclosed |
| US-20180092919-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME | NIPPON SHINYAKU CO., LTD. (JP) | 2018-04-05 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-9926322-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20180079751-A1 | PROCESS FOR PRODUCING PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-2773206-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9896453-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-02-20 | — | — | US | disclosed |
| EP-3281943-A1 | PROCESS FOR PRODUCING PURINONE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2018-02-14 | — | — | EP | disclosed |
| EP-3277677-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2018-02-07 | — | — | EP | disclosed |
| US-9884063-B2 | Amido-substituted azole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9879013-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-30 | — | — | US | disclosed |
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-01-04 | — | — | US | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20170369523-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS THAT ARE LIGANDS FOR G-PROTEIN-COUPLED RECEPTORS (GPCRS) AND ARE MODULATORS OF TRANSCRIPTION FACTORS AND COACTIVATORS | POLYPHOR AG (CH) | 2017-12-28 | — | — | US | disclosed |
| CN-104311573-B | Compounds that inhibit BTK and/or JAK3 kinase activity | 北京韩美药品有限公司 | 2017-12-15 | — | — | CN | disclosed |
| EP-3023415-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9834550-B2 | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| CN-107434803-A | Histone demethylase inhibitor | 吉利德科学公司 | 2017-12-05 | — | — | CN | disclosed |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| CN-105102456-B | Azaquinazoline inhibitors of atypical protein kinase C | 癌症研究技术有限公司 | 2017-11-14 | — | — | CN | disclosed |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170313706-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313705-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| CN-104662011-B | Treat the chroman derivative of mitochondrial disease | 康尊知识产权公司 | 2017-09-29 | — | — | CN | disclosed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| EP-3212647-A2 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | Dong-A ST Co., Ltd. (KR) | 2017-09-06 | — | — | EP | disclosed |
| EP-3209648-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170239351-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-24 | — | — | US | disclosed |
| US-20170231995-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | LUCID TRUSTEE SERVICES LIMITED (GB) | 2017-08-17 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
| US-9732082-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-20170224688-A1 | Methods of Using BTK Inhibitors to Treat Dermatoses | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| CN-104981458-B | Inhibitors of histone demethylases | 吉利德科学公司 | 2017-07-21 | — | — | CN | disclosed |
| WO-2017122175-A1 | THERAPEUTIC COMBINATIONS OF AN ANTIFOLATE AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2017-07-20 | — | — | WO | disclosed |
| EP-3190116-A1 | PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2017-07-12 | — | — | EP | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-3179991-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | Acerta Pharma B.V. (NL) | 2017-06-21 | — | — | EP | disclosed |
| EP-3179992-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | Acerta Pharma B.V. (NL) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017100668-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017093718-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-9670211-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017089587-A1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | WO | disclosed |
| US-20170152244-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170143712-A1 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | ACERTA PHARMA BV (NL) | 2017-05-25 | — | — | US | disclosed |
| US-20170136014-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2017-05-18 | — | — | US | disclosed |
| EP-3033341-B1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2017-05-03 | — | — | EP | disclosed |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170107259-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | POLYPHOR LTD. (CH) | 2017-04-20 | — | — | US | disclosed |
| EP-3150582-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9611219-B2 | — | — | 2017-04-04 | — | — | US | disclosed |
| US-9611220-B2 | — | — | 2017-04-04 | — | — | US | disclosed |
| EP-3145512-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2621923-B1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INT BV (NL) | 2017-03-29 | — | — | EP | disclosed |
| WO-2017046096-A1 | NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS FOR LOCAL DRUG DELIVERY | LEO PHARMA A/S (DK) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046746-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR AND A GITR BINDING MOLECULE, A 4-1BB AGONIST, OR AN OX40 AGONIST | ACERTA PHARMA B.V. (NL) | 2017-03-23 | — | — | WO | disclosed |
| US-9596852-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD. (CH) | 2017-03-21 | — | — | US | disclosed |
| WO-2017044828-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170071962-A1 | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-03-16 | — | — | US | disclosed |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| WO-2017033113-A1 | THERAPEUTIC COMBINATIONS OF A MEK INHIBITOR AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017025814-A1 | METHODS OF TREATING CANCERS, IMMUNE AND AUTOIMMUNE DISEASES, AND INFLAMMATORY DISEASES BASED ON BTK OCCUPANCY AND BTK RESYNTHESIS RATE | ACERTA PHARMA B.V. (NL) | 2017-02-16 | — | — | WO | disclosed |
| CN-106397418-A | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE公司 | 2017-02-15 | — | — | CN | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20170035756-A1 | METHODS OF BLOCKING THE CXCR-4/SDF-1 SIGNALING PATHWAY WITH INHIBITORS OF BRUTON'S TYROSINE KINASE | ACERTA PHARMA B.V. (NL) | 2017-02-09 | — | — | US | disclosed |
| US-20170035881-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-02-09 | — | — | US | disclosed |
| US-20170020886-A1 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| US-9538752-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD. (CH) | 2017-01-10 | — | — | US | disclosed |
| EP-3112368-A1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-01-04 | — | — | EP | disclosed |
| WO-2016210215-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| US-9521846-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD. (CH) | 2016-12-20 | — | — | US | disclosed |
| US-9518092-B2 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR LTD. (CH) | 2016-12-13 | — | — | US | disclosed |
| EP-2903968-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2805940-B1 | PYRAZINE CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160333051-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH PROTEASE INHIBITORY ACTIVITY | POLYPHOR LTD (CH) | 2016-11-17 | — | — | US | disclosed |
| CN-104193725-B | Organic compound | 诺华股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-106083887-A | The compound of suppression BTK and/or JAK3 kinase activity | 北京韩美药品有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-106065017-A | The compound of suppression BTK and/or JAK3 kinase activity | 北京韩美药品有限公司 | 2016-11-02 | — | — | CN | disclosed |
| WO-2016156816-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2016-10-06 | — | — | WO | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272617-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-22 | — | — | US | disclosed |
| US-20160264576-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-2786996-B1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160244437-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | disclosed |
| EP-2872502-B1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| WO-2016128912-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR, AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-08-18 | — | — | WO | disclosed |
| US-20160229853-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160222056-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-04 | — | — | US | disclosed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-9388192-B2 | Benzimidazole derivatives as Kinase Inhibitors | SELVITA S.A. (PL) | 2016-07-12 | — | — | US | disclosed |
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| EP-3033341-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9371325-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-21 | — | — | US | disclosed |
| WO-2016091916-A1 | PYRAZOLYLAMINOPURINES AS ITK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-16 | — | — | WO | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| WO-2016087994-A1 | BTK INHIBITORS TO TREAT SOLID TUMORS THROUGH MODULATION OF THE TUMOR MICROENVIRONMENT | ACERTA PHARMA B.V. (NL) | 2016-06-09 | — | — | WO | disclosed |
| CN-103153993-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (BS) | 2016-06-01 | — | — | CN | disclosed |
| EP-3023415-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-05-25 | — | — | EP | disclosed |
| WO-2016068580-A2 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122343-A1 | Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2016024230-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024227-A1 | BTK INHIBITORS TO TREAT SOLID TUMORS THROUGH MODULATION OF THE TUMOR MICROENVIRONMENT | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024228-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024231-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024232-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR AND/OR A CDK 4/6 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016020901-A1 | METHODS OF TREATING CANCERS, IMMUNE AND AUTOIMMUNE DISEASES, AND INFLAMMATORY DISEASES BASED ON BTK OCCUPANCY AND BTK RESYNTHESIS RATE | ACERTA PHARMA B.V. (NL) | 2016-02-11 | — | — | WO | disclosed |
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9199997-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| WO-2015178955-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20150336967-A1 | Novel Benzimidazole Derivatives as Kinase Inhibitors | Ryvu Therapeutics S.A. (PL) | 2015-11-26 | — | — | US | disclosed |
| CN-105102456-A | Azaquinazoline inhibitors of atypical protein kinase C | IGNYTA INC | 2015-11-25 | — | — | CN | disclosed |
| EP-2540736-B1 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2015-11-18 | — | — | EP | disclosed |
| US-20150274731-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO (JP) | 2015-10-01 | — | — | US | disclosed |
| CN-102827067-B | Beta-lactamase inhibitor | SCHERING CORPORATION (US) | 2015-09-23 | — | — | CN | disclosed |
| CN-102947285-B | Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases | ABBVIE (US) | 2015-08-26 | — | — | CN | disclosed |
| EP-2903968-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2015-08-12 | — | — | EP | disclosed |
| EP-2900666-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Ignyta, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| CN-102574861-B | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-08-05 | — | — | CN | disclosed |
| CN-102656179-B | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA Co.,Ltd. (CN) | 2015-07-29 | — | — | CN | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| EP-2540735-B1 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| EP-1622931-B1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-9073973-B2 | Dye conjugates of template-fixed peptidomimetics | POLYPHOR LTD. (CH) | 2015-07-07 | — | — | US | disclosed |
| WO-2015095492-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2872502-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| US-20150094299-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150087577-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | Universität Zürich (CH) | 2015-03-26 | — | — | US | disclosed |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| WO-2015022263-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015011252-A1 | PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2666774-B1 | Beta-lactamase Inhibitors | MERCK SHARP & DOHME (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8927590-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| EP-2167464-B1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBVIE DEUTSCHLAND (DE) | 2014-12-03 | — | — | EP | disclosed |
| EP-2805940-A1 | PYRAZINE CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8895695-B2 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR LTD. (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-8883791-B2 | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases | INTERVET INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883720-B2 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2014-11-11 | — | — | US | disclosed |
| US-20140330015-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-1363934-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | POLYPHOR LTD (CH) | 2014-10-08 | — | — | EP | disclosed |
| EP-2786996-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140213531-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH PROTEASE INHIBITORY ACTIVITIY | UNIVERSITAT ZURICH (CH) | 2014-07-31 | — | — | US | disclosed |
| CN-101910168-B | Tropane compounds | EXELIXIS INC | 2014-07-30 | — | — | CN | disclosed |
| US-20140187472-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | UNIVERSITAET ZUERICH (CH) | 2014-07-03 | — | — | US | disclosed |
| US-20140187471-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | UNIVERSITAET ZUERICH (CH) | 2014-07-03 | — | — | US | disclosed |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140107031-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS | POLYPHOR LTD. (CH) | 2014-04-17 | — | — | US | disclosed |
| WO-2014053491-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2014-04-10 | — | — | WO | disclosed |
| US-20140087994-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | UNIVERSITAET ZUERICH (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| CN-101918407-B | Beta-lactamase inhibitors | MERCK SHARP & DOHME | 2014-02-26 | — | — | CN | disclosed |
| US-8658604-B2 | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity | POLYPHOR LTD (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8633163-B2 | Template-fixed peptidomimetics | POLYPHOR LTD. (CH) | 2014-01-21 | — | — | US | disclosed |
| WO-2014009302-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| EP-2666774-A1 | Beta-lactamase Inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-1603570-B9 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274475-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-17 | — | — | US | disclosed |
| US-8557803-B2 | Purinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-15 | — | — | US | disclosed |
| EP-2231667-B1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| CN-103265477-A | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN INC | 2013-08-28 | — | — | CN | disclosed |
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130217880-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INC. | 2013-08-08 | — | — | US | disclosed |
| EP-2621923-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-8487093-B2 | β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| CN-103167867-A | Solid dispersions containing an apoptosis-inducing agent | ABBOTT LAB | 2013-06-19 | — | — | CN | disclosed |
| CN-103153993-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-06-12 | — | — | CN | disclosed |
| EP-2114986-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS | POLYPHOR LTD (CH) | 2013-05-22 | — | — | EP | disclosed |
| CN-103097352-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-05-08 | — | — | CN | disclosed |
| EP-2578585-A1 | PURINONE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130079327-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130053344-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| CN-102947285-A | Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases | ABBOTT LAB | 2013-02-27 | — | — | CN | disclosed |
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| EP-1603570-B1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2540736-A2 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | Polyphor AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540735-A2 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | Polyphor AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| CN-102827067-A | Beta-lactamase inhibitor | MERCK SHARP & DOHME | 2012-12-19 | — | — | CN | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8314120-B2 | Small molecule potentiators of metabotropic glutamate receptors | ABBOTT GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| CN-102656179-A | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA CO LTD | 2012-09-05 | — | — | CN | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2476667-A2 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2470536-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| WO-2012041872-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| US-8143261-B2 | Thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| WO-2012035055-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-03-22 | — | — | WO | disclosed |
| US-20110312879-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2011-12-22 | — | — | US | disclosed |
| US-20110294777-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-12-01 | — | — | US | disclosed |
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245155-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR LTD. (CH) | 2011-10-06 | — | — | US | disclosed |
| US-20110245247-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110230426-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110135576-A1 | DYE CONJUGATES OF TEMPLATE-FIXED PEPTIDOMIMETICS | POLYPHOR LTD. (CH) | 2011-06-09 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2324047-A2 | TEMPLATE-FIXED PEPTIDOMIMETICS | Polyphor Ag (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-2320734-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| US-7855179-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD. (CH) | 2010-12-21 | — | — | US | disclosed |
| CN-101918407-A | Beta-lactamase inhibitors | MERCK & CO INC | 2010-12-15 | — | — | CN | disclosed |
| CN-101910168-A | Tropane compounds | EXELIXIS INC | 2010-12-08 | — | — | CN | disclosed |
| US-7838496-B2 | Template-fixed peptidomimetics as medicaments against HIV and cancer | POLYPHOR AG/LTD. (CH) | 2010-11-23 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | WYETH LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100240592-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | POLYPHOR LTD. (CH) | 2010-09-23 | — | — | US | disclosed |
| US-7786078-B2 | Template-fixed δ-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR LTD. (CH) | 2010-08-31 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-7750155-B2 | Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100093644-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS | POLYPHOR LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2167464-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | Abbott GmbH & Co. KG (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-20100056432-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY | POLYPHOR LTD. (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015287-A2 | TEMPLATE-FIXED PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090281127-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090281123-A1 | NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS | ASTRAZENECA UK LIMITED | 2009-11-12 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20090264498-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009129370-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129371-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129365-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| EP-1622930-B9 | TEMPLATE-FIXED PEPTIDOMIMETICS AS MEDICAMENTS AGAINST HIV AND CANCER | POLYPHOR AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLA PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054345-A1 | Template-Fixed Beta-Hairpin Peptidomimetics With Protease Inhibitory Activity | POLYPHOR LTD. (CH) | 2009-02-26 | — | — | US | disclosed |
| EP-1458747-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS INHIBITORS OF SERINE PROTEASES | POLYPHOR LTD (CH) | 2009-02-11 | — | — | EP | disclosed |
| EP-2018388-A2 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018382-A2 | PURINE DERIVATIVES AS ADENOSINE RECEPTOR ACTIVATOR | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| WO-2008145616-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBOTT GMBH & CO. KG (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
| CN-100439371-C | 5, 7-diaminopyrazolo [4, 3-d ] pyrimidines useful in the treatment of hypertension | PFIZER LTD (GB) | 2008-12-03 | — | — | CN | disclosed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1981877-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1979374-A2 | TEMPLATE-FIXED PEPTIDOMIMETICS | Polyphor Ltd. (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20080227797-A1 | Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-7417024-B2 | Template-fixed peptidomimetics as inhibitors of serine proteases | POLYPHOR LTD. (CH) | 2008-08-26 | — | — | US | disclosed |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | ZEALAND PHARMA A/S (DK) | 2008-08-07 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| EP-1622930-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS MEDICAMENTS AGAINST HIV AND CANCER | POLYPHOR AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| EP-1549670-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | POLYPHOR LTD (CH) | 2008-04-30 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| EP-1348709-B1 | Thiazolo[4,5-d]pyrimidine compounds for the treatment of rheumatoid arthritis | ASTRAZENECA UK LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| EP-1638934-B1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| CN-101094846-A | 1- (hetero) aryl-3-amino-pyrrolidine derivatives as MGLUR3 receptor antagonists | LILLY CO ELI (US) | 2007-12-26 | — | — | CN | disclosed |
| CN-101090883-A | Substituted hydroxyethylamines | ELAN PHARM INC (US) | 2007-12-19 | — | — | CN | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| EP-1856140-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH PROTEASE INHIBITORY ACTIVITY | Polyphor Ltd. (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007121924-A2 | BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121917-A2 | PURINE DERIVATIVES AS ADENOSINE RECEPTOR ACTIVATOR | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007091703-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | WO | disclosed |
| US-7253146-B2 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD (CH) | 2007-08-07 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007079605-A2 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | POLYPHOR LTD. (CH) | 2007-07-19 | — | — | WO | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20070078079-A1 | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity | POLYPHOR LTD. (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070054840-A1 | Template-fixed peptidomimetics with antimicrobial activity | POLYPHOR LTD. (CH) | 2007-03-08 | — | — | US | disclosed |
| CN-1914205-A | Pyrazolo [3, 4-b ] pyridine compounds and their use as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2007-02-14 | — | — | CN | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060234923-A1 | Template-fixed peptidomimetics as medicaments against hiv and cancer | UNIVERSITAT ZURICH (CH) | 2006-10-19 | — | — | US | disclosed |
| WO-2006087001-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH PROTEASE INHIBITORY ACTIVITY | POLYPHOR LTD. (CH) | 2006-08-24 | — | — | WO | disclosed |
| EP-1680429-A1 | THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS | Celltech R & D Limited (GB) | 2006-07-19 | — | — | EP | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
| EP-1638979-A1 | THIENOPYRIDONE DERIVATIVES AS KINASE INHIBITORS | Celltech R & D Limited (GB) | 2006-03-29 | — | — | EP | disclosed |
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
| EP-1622930-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS MEDICAMENTS AGAINST HIV AND CANCER | Polyphor AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1620437-A1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050187145-A1 | Template-fixed peptidommetics as inhibitors of serine proteases | POLYPHOR LTD. (CH) | 2005-08-25 | — | — | US | disclosed |
| CN-1210279-C | Novel thiazolo (4, 5-D) pyrimidine compounds | ASTRAZENECA UK LTD (GB) | 2005-07-13 | — | — | CN | disclosed |
| EP-1549670-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | Polyphor Ltd. (CH) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005053663-A2 | NOREPINEPHRINE REUPTAKE INHIBITORS USEFUL FOR TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005042540-A1 | THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| EP-1503980-A2 | SUBSTITUTED HYDROXYETHYLAMINES | Elan Pharmaceuticals, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004113348-A1 | THIENOPYRIDONE DERIVATIVES AS KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004096839-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096838-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS AS MEDICAMENTS AGAINST HIV AND CANCER | POLYPHOR AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA UK LIMITED, A BRITISH CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-6790850-B1 | Thiazolo(4,5-d)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2004-09-14 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004033489-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | POLYPHOR LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
| EP-1222195-B1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2004-01-14 | — | — | EP | disclosed |
| EP-1363934-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | Polyphor Ltd. (CH) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
| EP-1348709-A2 | Thiazolo (4,5-D) pyrimidine compounds | AstraZeneca UK Limited (GB) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003072535-A2 | SUBSTITUTED HYDROXYETHYLAMINES | ELAN PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| CN-1402730-A | Thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA UK LTD (GB) | 2003-03-12 | — | — | CN | disclosed |
| WO-2002070547-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY | POLYPHOR LTD. (CH) | 2002-09-12 | — | — | WO | disclosed |
| EP-1138672-A1 | Process for the preparation of 3-amino-pyrrolidine derivatives | Basilea Pharmaceutica AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-5977381-A | Process for making 3-amino-pyrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0928787-A1 | Process for the preparation of 3-amino-pyrrolidine derivatives | F. Hoffmann-La Roche AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| US-5559120-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| US-5530121-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| US-5530007-A | ANTITUMOR, ANTIINFLAMMATORY, ANTIFUNGAL, ANTIPROLIFERATIVE, IMMUNOSUPPRESSIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| US-5508399-A | USEFUL AS IMMUNOSUPPRESSANT, ANTIINFLAMMATORY, ANTIFUNGAL, ANTIPROLIFERATIVE AND ANTIUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-5480989-A | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0394685-A2 | (S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid | WARNER-LAMBERT COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4916141-A | ANTIBACTERIAL | WARNER-LAMBERT COMPANY (US) | 1990-04-10 | — | — | US | disclosed |
| US-4851418-A | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0304087-A2 | Quinolone and naphthyridine antibacterial agents containing an alpha-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
| EP-0304087-A2 | Quinolone and naphthyridine antibacterial agents containing an alpha-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |